Leukemia Posts on Medivizor
Navigation Menu

Leukemia Posts on Medivizor

Could interferon-alpha benefit acute leukemia patients who have minimal residual disease after stem cell transplants?

Posted by on Aug 19, 2017 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness of interferon-alpha (IFN-α) in acute leukemia patients with minimal residual disease after stem cell transplantation. This study concluded that IFN-α is an effective treatment for acute leukemia patients with minimal residual disease after stem cell...

Read More

Outcomes for patients with relapsed or refractory acute leukemia receiving donor lymphocyte infusions after stem cell transplant

Posted by on Aug 14, 2017 in Leukemia | 0 comments

In a nutshell This study examined whether donor lymphocyte infusion (DLI) can reduce the risk of relapse after stem cell transplantation in patients with relapsed or refractory acute leukemia. Researchers reported improved outcomes among patients receiving multiple DLIs guided by the presence of minimal residual disease or graft-versus-host...

Read More

Targeted therapies: Ibrutinib appears superior to idelalisib as first treatment

Posted by on Aug 14, 2017 in Leukemia | 0 comments

In a nutshell This study examined the order of treatment with ibrutinib (Imbruvica), idelalisib (Zydelig), and venetoclax (ABT-199) for chronic lymphocytic leukemia (CLL). Researchers concluded that ibrutinib appears superior to idelalisib as first treatment. Some background Early studies are reporting promising results with targeted therapies for...

Read More

Is there a benefit of reduced-intensity conditioning plus imatinib compared to imatinib alone?

Posted by on Aug 14, 2017 in Leukemia | 0 comments

In a nutshell This study examined two types of treatment regimes involving imatinib (Gleevac) for chronic myeloid leukemia (CML). Patients receiving reduced-intensity chemotherapy and a stem cell transplant before imatinib had similar outcomes to patients treated with imatinib alone. Some background Targeted therapy has become the standard...

Read More

Imatinib is safe and effective for long-term CML treatment

Posted by on Aug 7, 2017 in Leukemia | 0 comments

In a nutshell This study examined the results of a 10 year imatinib (Gleevec) clinical trial. The study concluded that imatinib is a safe and effective treatment for CML. Some background Chronic myeloid leukemia (CML) is a disease in which the bone marrow makes too many mature and immature white blood cells. CML is a slowly progressing blood and...

Read More

Is hematopoietic cell transplantation a good option for those with primary acute lymphoblastic leukemia that has not responded to treatment?

Posted by on Aug 7, 2017 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the outcomes of hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia. This study concluded that hematopoietic cell transplantation is of benefit to patients with primary refractory acute lymphoblastic leukemia. Some background Acute lymphoblastic leukemia (ALL)...

Read More

An overview of treatment options for older AML patients

Posted by on Aug 6, 2017 in Leukemia | 0 comments

In a nutshell This study reviewed treatment strategies for older patients with acute myeloid leukemia (AML). Some background AML is a cancer of the blood and bone marrow that mainly affects the elderly. The average age at diagnosis is 67 years. While advances in AML treatment have increased survival, outcomes for the elderly remain...

Read More

Remaining leukemia cells have a negative impact on stem cell transplantation in AML

Posted by on Jul 30, 2017 in Leukemia | 0 comments

In a nutshell This study looked at the effect of remaining leukemia cells (present in bone marrow during remission) on stem cell transplant outcomes in acute myeloid leukemia patients. The study concluded that the presence of leukemia cells prior to stem cell transplantation has a negative effect on patient outcomes.  Some background Adult...

Read More